Resources
Straight answers for peptide merchants.
Compliance, underwriting, and payment processing explained plainly — so you can make informed decisions about your processing setup.
Articles
What every peptide merchant should know
Guides written for research-use-only and Rx-licensed businesses navigating payment processing.
How to legally run a peptide company in 2026
A plain-English operating model for a defensible peptide business: lawful product pathways, the right entity, restricted marketing, and an examiner-ready payments file.
Read article → ComplianceIs it legal to sell peptides? The four lawful pathways
Selling peptides is legal only inside one of four FDA pathways. Here is what each one (FDA-approved, 503B, 503A, and research/IND) requires — and what falls outside the law.
Read article → Compliance503A vs 503B for peptides: which compounding pathway fits?
The difference between 503A and 503B decides whether you can sell office stock, who can be the seller, and what you can compound. Here is the practical breakdown for peptides.
Read article → ComplianceWhy "research use only" peptides can't be sold for human use
Selling RUO or "not for human consumption" peptides into the physician-to-patient channel is one of the highest-risk models in the industry. Here is why — and what the FDA has said.
Read article → ComplianceSelling GLP-1 peptides (semaglutide, tirzepatide) legally
GLP-1 and GLP-1-adjacent peptides carry unusually high regulatory risk. Here is the hardline policy a bankable business needs — and what the FDA has said about compounding them.
Read article → ComplianceShould your peptide company be the merchant of record?
For most peptide platforms, the answer is no. Being the merchant of record for the drug can make you look like the seller — and trigger 503B, anti-kickback, and corporate-practice-of-medicine risk.
Read article → CompliancePeptide marketing compliance: claims you can and can't make
For a defensible peptide business, marketing is B2B professional education — not consumer demand generation. Here is the allowed/prohibited list, grounded in FTC substantiation rules.
Read article → ComplianceAnti-kickback rules for peptide sales: commissions and inducements
Commission structures, rebates, and provider inducements are where compliant peptide businesses quietly go wrong. Here is how to structure payments without triggering anti-kickback risk.
Read article → ComplianceHow to get a peptide merchant account approved
Peptide merchant accounts get approved — and stay approved — when the program can hand an examiner a complete, current compliance file. Here is what the bank actually wants to see.
Read article → ComplianceThe peptide compliance checklist: the 13-question boardable test
A peptide payments program is "boardable" only when the answer to all 13 questions is Yes. A single No is a stop. Here is the full pass/fail checklist.
Read article → ComplianceHow to not get your peptide merchant account shut down
A step-by-step operating playbook to keep a peptide merchant account boarded: what triggers a shutdown, the controls that prevent it, and the warning signs that mean you have days, not months.
Read article → Compliance10 things to know when selling BPC-157
BPC-157 is one of the most searched peptides and one of the hardest to sell lawfully. Ten things every seller should understand about its regulatory status, marketing limits, and payment acceptance.
Read article →Why peptide businesses get their merchant accounts frozen (and how to avoid it)
Account terminations rarely come with warning. Understanding the real risk triggers behind frozen peptide merchant accounts is the first step to staying boarded.
Read article →Research-use-only vs. consumer sales: what compliant peptide processing requires
The distinction between RUO B2B sales and consumer-facing health claims is the single most important compliance line for peptide payment processing. Here's how underwriters read it.
Read article →What to look for when reading your processing statement
Most merchants never read their processing statements closely enough to know what they are actually paying. Here is what to look for — and what the numbers tell you about your risk exposure.
Read article →Choosing a high-risk payment processor that won't disappear in 90 days
The high-risk processing market is full of providers who board quickly, make promises they cannot keep, and exit relationships just as fast. Here is how to evaluate a processor before you commit.
Read article →Ready to see what your statement actually says?
A free 24-hour review covers your cost structure, risk flags, and underwriting readiness — no obligation.